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Patients who undergo allogeneic stem cell transplantation frequently develop an immunologic disease caused
by the reactivation of the graft to the host tissues. This disease is called graft-versus-host disease (GVHD) and it
is usually a systemic disorder. In a large proportion of cases, oral disorders that are related to a chronic phase of
GVHD (cGVHD) occur, and their treatment involves the use of topical immunosuppressive drugs. Several
medications have been studied for this purpose, but only a small number of clinical trials have been published.
The present study is a randomized, double-blind clinical trial that compares topical clobetasol and dexa-
methasone for the treatment of symptomatic oral cGVHD. Patients were randomly assigned to treatment with
clobetasol propionate .05% or dexamethasone .1 mg/mL for 28 days. In both arms, nystatin 100,000 IU/mL was
administered with the corticosteroid. Oral lesions were evaluated by the modiﬁed oral mucositis rating scale
(mOMRS) and symptomswere registered using a visual analogue scale. Thirty-ﬁve patients were recruited, and
32 patients were randomized into the study groups: 18 patients (56.3%) to the dexamethasone group and
14 patients (43.8%) to the clobetasol group. The use of clobetasol resulted in a signiﬁcant reduction in mOMRS
total score (P ¼ .04) and in the score for ulcers (P ¼ .03). In both groups, there was signiﬁcant symptomatic
improvement but the response was signiﬁcantly greater in the clobetasol group (P ¼ .02). In conclusion, clo-
betasol was signiﬁcantly more effective than dexamethasone for the amelioration of symptoms and clinical
aspects of oral lesions in cGVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION Several medications have been studied for the topical
Chronic graft-versus-host disease (cGVHD) is an impor-
tant late complication in allogeneic hematopoietic stem cell
transplant (HSCT) recipients [1]. In this setting, oral cavity
involvement with cGVHD is frequent, with an estimated
prevalence of 80% to 100% of cases [2,3]. Oral cGVHD lesions
have clinical and pathological characteristics very similar to
those of oral lichen planus (OLP) [3-5]. According to the
National Institutes of Health (NIH) consensus criteria for
cGVHD [1], the clinical oral manifestations of cGVHD include
lichenoid lesions, pseudomembrane ulceration, atrophy,
erythema, and mucoceles. The criteria also consider symp-
toms, including oral sensitivity, pain, taste disturbances, and
dry mouth [6,7]. Oral lesions of chronic GVHD are commonly
refractory to immunosuppressive systemic therapy; there-
fore, the addition of topical agents to systemic therapy is
frequently necessary [2,8,9]. Despite this knowledge, there is
no deﬁned recommendation for the topical treatment of
cGVHD oral lesions.dgments on page 1167.
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14.04.009treatment of these lesions, such as azathioprine, tacrolimus,
dexamethasone, and budesonide [10-19]. These studies have
shown that topical treatment results in improvement of the
clinical or symptomatic aspects of the oral lesions; however,
these were case reports or series of cases. The results of
previous clinical trials have shown that topical treatment
improves the clinical aspects of the lesions and provides
better results than systemic treatment alone [13,19,20].
The present study was a randomized, double-blind
clinical trial comparing 2 topically administered corticoste-
roids (clobetasol versus dexamethasone) for symptomatic
cGVHD oral lesions. As clobetasol has been shown to have
greater potency than dexamethasone [21,22], we hypothe-
sized that clobetasol would provide a better response than
dexamethasone.
MATERIALS AND METHODS
This study was designed as a randomized, double-blind clinical trial.
Patients were recruited from the Clementino Fraga Filho University Hospital
of the Federal University of Rio de Janeiro and from the Hematology and
Hemotherapy Center of the Campinas University (Hemocentro/Unicamp)
from October 2008 to May 2012. Patients with oral lesions of cGVHD were
asked if they presented sensitivity on the oral mucosa. All the patients who
presented symptomatic oral lesions of cGVHD were invited to participate in
the study. They were informed of the aims, risks, and beneﬁts of the study
and signed a consent form. Patients who fulﬁlled the inclusion criteria wereTransplantation.
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Patients with a history of allergy to the tested medications, as well as those
under topical treatment for oral lesions of cGVHD in the last 3 months, were
excluded from the study. Systemic immunosuppressive treatments were not
considered as an exclusion criteria. This research was approved by the re-
view boards of both institutions and was registered in ClinicalTrials.gov
under the identiﬁer NCT01699412.
Because there are few clinical trials on oral cGVHD, the sample size of
the present study was calculated based on studies of OLP. The expected
symptomatic improvement was 100% for the clobetasol group and 38.5% for
the dexamethasone group [23,24]. Using a signiﬁcance of 95% and power of
80%, the sample size was calculated as 30 patients with 15 patients in each
study group. Accounting for an expected loss of 20% from protocol inclusion
and randomization, we aimed to enroll 38 patients.
Randomization
Patients included in the study were randomly assigned to 1 of 2 study
groups using Random Allocation Software 1.0 (Isfahan University of Medical
Sciences, Isfahan, Iran). Randomization was performed at a central location.
One group rinsed their mouths with 5 mL of a solution of clobetasol
propionate .05% administered with nystatin 100,000 IU/mL and the other
group rinsed with 5 mL of a solution of dexamethasone .1 mg/mL admin-
istered with nystatin 100,000 IU/mL. Patients were instructed to use the
solution for 1 minute timed by a clock, 3 times a day, for 28 days.
Both medications were prepared centrally at the School of Pharmacy of
Federal University of Rio de Janeiro. Both solutions had similar taste, color,
and smell; labels were numbered and did not identify the medication.
Data Collection
Clinical and demographic characteristics of the patients were obtained
from medical records. Clinical evaluations were performed at baseline and
after 28 days of treatment using symptomatic and morphologic criteria.
Symptoms (oral sensitivity, pain, and xerostomia) were recorded by the
patients using a visual analogue scale (VAS) [4,25,26]. Patients were evalu-
ated by an oral medicine expert whowas familiar with the evaluation of oral
cGVHD lesions. Oral lesions of cGVHD were diagnosed according to the NIH
consensus criteria for cGVHD and graded by the modiﬁed Oral Mucositis
Rating Scale (mOMRS) [1,27]. Biopsy was performed in cases in which
cGVHD had not been previously established. Adherence to treatment
and adverse effects were analyzed at the end of the treatment, through a
questionnaire.
Primary Outcome
The primary study outcome was the improvement of symptoms.
Patients were asked to mark in a VAS how much sensitivity they presented
on the oral mucosa. Oral sensitivity was considered when the patient
reported symptoms greater than 0 on the VAS. Symptomatic improvement
was deﬁned as the range between the VAS before and after therapy. The
improvement was categorized as (1) total remission, ie, reduction in the VAS
to 0; (2) partial remission, ie, reduction of at least 2 cm in VAS; and (3) no
remission, ie, changes not greater than 2 cm in VAS. Patients who presentedFigure 1. Flow chart of patientVAS at baseline lower than 2 cm, and who showed reduction to 0 on VAS
at the end of the treatment, were considered as total remission. Median
reductions in the differences in the VAS scores were compared between the
study groups (VAS at baseline less VAS at the end of the topical treatment).
Secondary Outcomes
Morphologic improvement was considered as a secondary outcome and
was deﬁned as the total reduction in mOMRS total score throughout the
study (mOMRS total score at baseline less mOMRS total score at the end of
the topical treatment). Additionally, the median reductions in the mOMRS
scores for erythema, lichen-type hyperkeratosis, ulcers, andmucoceles were
compared between the study groups.
Additionally, oral dryness was evaluated by the presence of xerostomia
and by measuring salivary ﬂow rates (SFR). Patients were asked to mark in a
VAS howmuch dryness they presented in the mouth. To analyze the cases of
persistent daily dry mouth, xerostomia was considered only when scored as
 2 cm on VAS. The median VAS scores for xerostomia at baseline and at the
end of the topical treatment were compared between the study groups.
Resting saliva samples were collected under standard conditions, after the
oral evaluation [28,29]. Reduced SFR was considered when measured
as< .3 mL/minute [30]. The median resting SFR at baseline and at the end of
the topical treatment were compared between the study groups.
Statistical Analysis
All statistical analysis was performed using SPSS for Windows software
(version 17.0, IBM, Chicago, IL). The chi-square test or Fisher exact test was
used to compare proportions, and the Mann-Whitney and Wilcoxon tests
were used to compare continuous variables. P values < .05 were considered
statistically signiﬁcant.
RESULTS
A total of 35 patients were recruited for the study. Three
patients were excluded (2 patients were under topical
treatment for oral cGVHD,1 patient declined to participate in
the study). Thirty-two patients were randomized into the
study groups: 18 patients (56%) to the dexamethasone group
and 14 patients (44%) to the clobetasol group (Figure 1).
Clinical and demographic data on the 32 studied patients
are summarized in Table 1. Most patients had GVHD classi-
ﬁed as overlap syndrome (66.7%) and were receiving some
systemic treatment for GVHD (62.5%). The ﬁrst study evalu-
ation was performed at a median of 471 days (range, 83 to
2405 days) after the HSCT. The most commonly affected
organs were skin (56%), liver (47%), and eye (44%). The
observed oral manifestations of cGVHD at baseline are pre-
sented in Table 2. On baseline exam, erythema and atrophy
were present in 91% and 81% of patients, respectively. Ulcers,s throughout the study.
Table 1
Demographic and Clinical Characteristics
Variables Total Clobetasol Group Dexamethasone Group
No. of patients 32 14 18
Gender
Male 14 (43.8) 6 (42.9) 8 (44.4)
Female 18 (56.3) 8 (57.1) 10 (55.6)
Age, median (range), yr 49.5 (27-66) 53.00 (29-60) 45.50 (27-66)
Underlying disease
Chronic myeloid leukemia 9 (28.1) 5 (35.7) 4 (22.2)
Acute myeloid leukemia 8 (25.0) 2 (14.3) 6 (33.3)
Acute lymphocytic leukemia 3 (9.4) 2 (14.3) 1 (5.6)
Hodgkin lymphoma 3 (9.4) 2 (14.3) 1 (5.6)
Chronic lymphocytic leukemia 2 (6.3) 1 (7.1) 1 (5.6)
Non-Hodgkin lymphoma 2 (6.3) 1 (7.1) 1 (5.6)
Myeloﬁbrosis 2 (6.3) 1 (7.1) 1 (5.6)
Multiple myeloma 1 (3.1) – 1 (5.6)
Aplastic anemia 1 (3.1) – 1 (5.6)
Myelodysplastic syndrome 1 (3.1) – 1 (5.6)
Conditioning regimen
Busulfan and cyclophosphamide 19 (61.3) 8 (57.1) 11 (64.7)
Fludarabine and TBI 5 (15.6) 2 (14.3) 3 (17.6)
Fludarabine and melphalan 3 (9.7) 1 (7.1) 2 (11.8)
Busulfan, cyclophosphamide, and etoposide 2 (6.5) 1 (7.1) 1 (5.9)
Busulfan, cyclophosphamide and ﬂudarabine 1 (3.2) 1 (7.1) –
Busulfan and ﬂudarabine 1 (3.2) 1 (7.1) –
Source of stem cells for HSCT*
Peripheral blood 17 (70.8) 8 (80.0) 9 (64.3)
Bone marrow 7 (29.2) 2 (20.0) 5 (35.7)
Time post-HSCT, median (range), d 471.5 (83-2405) 634.50 (83-2405) 427.50 (159-1986)
History of acute GVHD
Yes 9 (28.1) 4 (28.6) 5 (27.8)
No 23 (71.9) 10 (71.4) 13 (72.2)
NIH classiﬁcation*
Overlap syndrome 18 (66.7) 8 (72.7) 10 (62.5)
Classic chronic GVHD 9 (33.3) 3 (27.3) 6 (37.5)
Systemic treatment for cGVHD
None 12 (37.5) 6 (42.9) 6 (33.3)
Prednisone and cyclosporine 12 (37.5) 3 (21.4) 9 (50.0)
Prednisone, cyclosporine, and mycophenolate 3 (9.4) 3 (21.4) –
Cyclosporine 2 (6.3) 1 (7.1) 1 (5.6)
Prednisone 2 (6.3) 1 (7.1) 1 (5.6)
Prednisone and mycophenolate 1 (3.1) – 1 (5.6)
Organs affected by cGVHD
Skin 18 (56.3) 10 (71.4) 8 (44.4)
Liver 15 (46.9) 6 (42.9) 9 (50.0)
Eyes 14 (43.8) 8 (57.1) 6 (33.3)
Gut 2 (6.3) 1 (7.1) 1 (5.6)
Muscles, fascia, and joints 2 (6.3) 2 (14.3) –
Lungs 2 (6.3) 2 (14.3) –
TBI indicates total body irradiation; HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; NIH, National Institutes of Health; cGVHD,
chronic graft-versus-host disease.
Data presented are n (%), unless otherwise indicated.
* In some cases, data on NIH classiﬁcation and source of stem cells were missing from medical records.
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60% of patients, respectively. These lesions were distributed
in the buccal and labial mucosa, tongue, gingival, and hard
palate. No statistical signiﬁcance was observed between the
groups with regard to clinical demographic characteristics or
oral manifestations of cGVHD at baseline.
The median VAS for oral sensitivity was 4.7 (range, 1.4 to
10). Xerostomia was observed in 75% of the cases, with a
median VAS of 4.75. Reduced SFR was present in 63.3% of the
cases. No statistical signiﬁcance was observed between the
groups with regard to VAS scores for oral sensitivity and
xerostomia at baseline. Data on oral sensitivity, xerostomia,
and resting SFR are presented in Table 3.
After the scheduled 28 days of topical treatment, 2
patients had discontinued the topical medication and 2 did
not attend the ﬁnal evaluation. Thus, 28 patients were
evaluated for treatment response (13 in the clobetasolgroup and 15 in the dexamethasone group).
Systemic therapy was not altered during the study period
in 17 patients (60.7%), whereas 9 patients (32.1%) reduced
the dose of the systemic therapy. In only 2 cases (7.2%), the
dose of the systemic therapy was increased; both of
these patients had been randomized for the clobetasol
group.
The number of treated patients with symptomatic
improvementwas signiﬁcantly higher in the clobetasol group
than in the dexamethasone group (P ¼ .02). Eleven patients
(85%) showed at least partial remission of symptoms in the
clobetasol group compared with only 5 (33%) in the dexa-
methasone group (Table 4). Additionally, the median reduc-
tion in the symptomatic response (VAS) was signiﬁcantly
better for the clobetasol group than for the dexamethasone
group (reduction of 2.1 cm and 1.4 cm, respectively; P ¼ .02)
(Figure 2).
Table 2
Oral Manifestations of cGVHD at Baseline Evaluation
Variable Total Clobetasol
Group
Dexamethasone
Group
No. of patients 32 14 18
Oral lesions of cGVHD*
Erythema 29 (90.6) 12 (85.7) 17 (94.4)
Atrophy 26 (81.3) 13 (92.9) 13 (72.2)
Ulcer 22 (68.8) 11 (78.6) 11 (61.1)
Lichen 21 (65.6) 11 (78.6) 10 (55.6)
Hyperkeratosis 19 (59.4) 8 (57.1) 11 (61.1)
Pseudomembrane 3 (9.4) 1 (7.1) 2 (11.1)
Edema 2 (6.3) 2 (14.3) –
Mucocele 14 (43.8) 5 (35.7) 9 (50.0)
Oral sites with lesions*
Buccal mucosa 29 (90.6) 13 (92.9) 16 (88.9)
Tongue 27 (84.4) 13 (92.9) 14 (77.8)
Gingiva 25 (78.1) 12 (85.7) 13 (72.2)
Hard palate 24 (75.0) 12 (85.7) 12 (66.7)
Vermillion 19 (59.4) 8 (57.1) 11 (61.1)
Labial mucosa 19 (59.4) 6 (42.9) 13 (72.2)
Soft palate 9 (28.1) 2 (14.3) 7 (38.9)
Floor of the mouth 5 (15.6) 2 (14.3) 3 (16.7)
cGVHD indicates chronic graft-versus-host disease.
Data presented are n (%), unless otherwise indicated.
* Some patients presented with more than 1 type of lesion, and lesions
could be located in more than 1 anatomical site.
Table 4
Symptomatic Response to Treatment according to the Study Group
Categorized
Symptomatic Response
Clobetasol
Group (n ¼ 13)
Dexamethasone
Group (n ¼ 15)
P Value
Total remission 3 (23.1) 1 (6.7) .02
Partial remission 8 (61.5) 4 (26.7)
No remission 2 (15.4) 10 (66.7)
Data presented are n (%), unless otherwise indicated.
Four patients had no evaluation of response (two patients had discontinued
the topical medication and two did not attend the ﬁnal evaluation).
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showed that the median reduction inmOMRS total score was
signiﬁcantly higher in the clobetasol group than the reduc-
tion observed in the dexamethasone group (3.0 and 1.0,
respectively; P ¼ .03) (Figure 3). Moreover, patients in
the clobetasol group presented a 3-point reduction in the
median mOMRS scores for ulcers, whereas no reduction was
observed in patients using dexamethasone (P ¼ .04). In both
groups, no signiﬁcant reductions were observed in the
mOMRS scores for erythema (P ¼ .88), lichen-type hyper-
keratosis (P ¼ .09), and mucoceles (P ¼ .71). In 53.9% of the
cases, the use of clobetasol resulted in an improvement of at
least 50% in the mOMRS total score; for dexamethasone, this
result was observed in 26.7% of the patients (P ¼ .34).
Xerostomia, as analyzed through median VAS scores, was
signiﬁcantly improved in patients in the dexamethasone
group (baseline 5.15 cm; ﬁnal evaluation 3.40 cm; P¼ .04) but
not in the clobetasol group (baseline 4.10 cm; ﬁnal 4.00 cm;
P ¼ .06). A signiﬁcant increase in the median SFR in the clo-
betasol group was noted when the baseline and ﬁnal evalu-
ations were compared (.19 mL/minute and .30 mL/minute,
respectively; P ¼ .01). No signiﬁcant differences in SFR were
observed in the dexamethasone group (P ¼ 1.00).
Only 2 patients reported adverse events, both of whom
reported a burning sensation (1 patient used clobetasol and 1
used dexamethasone). This complaint was the reason given
by the patient in the dexamethasone group who dis-
continued the topical treatment. No cases of candidiasis were
observed during the study period.Table 3
Oral Sensitivity, Xerostomia, and Salivary Flow Rate at Baseline Evaluation
Variables Total
N ¼ 32
VAS for sensitivity of oral lesions 4.70 (1.4-10.0) cm
VAS for xerostomia 4.75 (0.0-10.0) cm
Resting salivary ﬂow rate .24 (.02-1.6) mL/min
VAS indicates visual analogue scale.
Data presented are median (range).DISCUSSION
In the present study, topical clobetasol was signiﬁcantly
more effective than topical dexamethasone in reducing the
symptoms of oral cGVHD, with 85% of patients experiencing
at least a partial response. It was also more effective in
improving morphologic lesions than topical dexamethasone,
with the exception of xerostomia.
Symptomatic response is an intriguing outcome for
analysis in patients with oral GVHD in light of the high
complexity of their pathology, as well as the impact on
quality of life [3]. In addition, the recommendation for the
initiation of therapy is based on symptoms and reestablish-
ment of mucosal barrier [31]. So far, studies with topical
clobetasol or dexamethasone for oral cGVHD are limited to
case reports or series of cases [14,17]. Moreover, the only
clinical trial of topical treatment for oral cGVHD using
dexamethasone focused on morphologic lesion improve-
ment, with no data regarding symptomatic response [19].
Thus, the results from the present studywere compared with
those for topical treatment of OLP [3,16].
In OLP studies, clobetasol had been associated with better
outcomes comparedwith dexamethasone. However, different
treatment regimens have been proposed in the literature.
Previous studies have used .05% topical clobetasol applica-
tions, 2 or 3 times a day, for a period between 2 weeks
and 2 months. Topical dexamethasone has been used in a
.1 mg/mL solution or in a .043% paste, 3 to 4 times a day, for
1 month. Hence, it is to be expected that different treatment
regimens produce variable results. Reported symptomatic
improvement of OLP lesions varied from 63.6% to 100% with
topical clobetasol, and from 38.50% to 72.51% with topical
dexamethasone [23,24,32-34]. In the present study, evenwith
fewer treated patients, symptomatic improvement was
observed 2.5 times more frequently in clobetasol-treated
patients than in patients treated with dexamethasone.
With regard to morphologic response, clinical trials with
clobetasol for OLP lesions showed improvement in 13.6%
to 77.27% of the cases [23,32,33]. In the present study, a
reduction in the scores for oral cGVHD lesions was observed
in one half of the patients who received topical clobetasol,
which underscores the complexity and treatment difﬁculty
associatedwith this pathology. The dexamethasone response
was even lower, with only 27% of patients with improvement
in our series. Such result is similar to a recent study, whichClobetasol Group
n ¼ 14
Dexamethasone Group
n ¼ 18
4.25 (1.7-10.0) cm 5.00 (1.4-9.7) cm
4.10 (0.0-10.0) cm 5.15 (.2-9.0) cm
.19 (.02-1.6) mL/min .24 (.02-.84) mL/min
Figure 2. Box plot graph showing the differences in the reduction (DS) in
visual analogue scale (VAS) for sensitivity of oral lesions, according to the
study groups.
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topical therapy with .01% dexamethasone for 1 month [35]. A
previous study conducted by Wolff et al., which included 16
patients with oral cGVHD, reported a morphologic response
in 68.75% of the cases treated with topical dexamethasone
[19]. A possible reason for this difference may be attributed
to the duration of the topical therapy or the length of time of
outcome evaluation. Indeed, the present study performed
the ﬁnal evaluation after 28 days of treatment. Wolff et al., on
the other hand, reported the outcome after the end of ther-
apy, but the duration of the topical therapy in their study
varied from 12 days to 9 months. These results suggest that
the clinical responses of oral cGVHD lesionsmay beneﬁt from
prolonged periods of topical therapy.
Manifestations of cGVHD in the salivary glands were
very frequent in our patients, which included xerostomia,
reduced SFR, and the presence of mucoceles. Although sicca
syndrome is a well-documented disorder in GVHD patients,
the NIH deﬁnes lacrimal dysfunction and xerostomia as
GVHD criteria, and no recommendations have been provided
for salivary gland involvement by cGVHD [1,27,35-37]. Sali-
vary gland and oral mucosal involvement seem to be distinct
manifestations of cGVHD and not extensions of the same
pathologic process [36].
An unexpected increase in the resting SFR in patients
using topical clobetasol was observed in the present study.
Clobetasol is known to penetrate the oral mucosa, especially
in the presence of atrophic or ulcerated mucosal lesions [38].
The permeability of the oral mucosa is estimated to be 4 to
4000 times greater than that of the skin [39]. Thus, clobetasol
may be able to penetrate the oral mucosa, reduce theFigure 3. Box plot graph showing the differences in the reduction (DM) in the
modiﬁed oral rating scale (mOMRS) total score, according to the study groups.inﬂammatory process in the minor salivary glands, and,
consequently, increase the resting SFR. However, we did not
observe any improvement in symptomatic xerostomia in this
group. On the other hand, patients treated with dexameth-
asone, despite no improvement in SFR, reported beneﬁts in
xerostomia. Further research is required to better assess the
efﬁcacy of topical therapy on the salivary glands affected by
cGVHD, as well as the factors related to morphologic and
symptomatic outcomes.
There were some limitations in the present study. The
main limitation was the small number of patients enrolled.
The scant sample size exposed our analysis to the presence of
confounding variables, such as immunosuppressive treat-
ment, duration of topical therapy, and salivary ﬂow rates.
Further research should be designed, with larger samples, to
stratify groups for the inﬂuence of these variables on the
topical therapy for oral cGVHD lesions. Additionally, patients
included in this series had experienced long intervals after
their HSCT procedures. Thus, our patients most likely reﬂect
patients with difﬁcult-to-treat cGVHD and those with a high
frequency of systemic disorders. Furthermore, the response
rates to the topical treatment were analyzed at a speciﬁc
point in time. An analysis using “time to event” might offer
greater insight into the impact of these treatment choices.
In conclusion, the present study showed that topical
clobetasol or dexamethasone was efﬁcacious in the reduc-
tion of symptoms related to oral cGVHD. However, clobetasol
was signiﬁcantly more effective than dexamethasone in the
symptomatic and morphologic improvement of oral lesions.ACKNOWLEDGMENTS
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